Products
Alnuctamab Biosimilar Bispecific Antibody (BCMA × CD3) for Research
Pre-made Alnuctamab benchmark antibody (Bispecific mAb with Domain Crossover, anti-TNFRSF17;CD3E therapeutic antibody, Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-018-1mg | 1mg | |
| GMP-Bios-ab-018-10mg | 10mg | |
| GMP-Bios-ab-018-100mg | 100mg | |
| GMP-Bios-ab-018-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Alnuctamab biosimilar, Bispecific mAb with Domain Crossover, Anti-TNFRSF17;CD3E Antibody: Anti-BCM/BCMA/CD269/TNFRSF13A;T3E/TCRE/IMD18 therapeutic antibody |
| INN Name | Alnuctamab |
| Target | TNFRSF17;CD3E |
| Format | Bispecific mAb with Domain Crossover |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1;G1 |
| VD LC | Kappa;Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | Celgene Corporation |
| Conditions Approved | na |
| Conditions Active | Multiple myeloma |
| Conditions Discontinued | na |
| Development Tech | na |
About target - TNFRSF17
1. Protein Tumor necrosis factor receptor superfamily member 17
2. Gene TNFRSF17
3. Organism Homo sapiens (Human)
Function
Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK.
